ChemoCentryx, Inc. (CCXI) Insider Petrus Bekker Sells 30,000 Shares
ChemoCentryx, Inc. (NASDAQ:CCXI) insider Petrus Bekker sold 30,000 shares of the business’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $9.98, for a total value of $299,400.00. Following the completion of the transaction, the insider now directly owns 65,963 shares of the company’s stock, valued at $658,310.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Petrus Bekker also recently made the following trade(s):
- On Tuesday, July 11th, Petrus Bekker sold 30,000 shares of ChemoCentryx stock. The shares were sold at an average price of $9.78, for a total value of $293,400.00.
- On Thursday, July 13th, Petrus Bekker sold 76,013 shares of ChemoCentryx stock. The shares were sold at an average price of $9.95, for a total value of $756,329.35.
- On Monday, July 10th, Petrus Bekker sold 19,877 shares of ChemoCentryx stock. The shares were sold at an average price of $9.30, for a total value of $184,856.10.
- On Friday, June 30th, Petrus Bekker sold 65,509 shares of ChemoCentryx stock. The shares were sold at an average price of $9.17, for a total value of $600,717.53.
Shares of ChemoCentryx, Inc. (NASDAQ CCXI) opened at 10.14 on Wednesday. The company’s market cap is $488.47 million. The company’s 50-day moving average price is $9.47 and its 200 day moving average price is $7.68. ChemoCentryx, Inc. has a 12-month low of $3.95 and a 12-month high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.14. The firm had revenue of $8.23 million for the quarter. Equities analysts predict that ChemoCentryx, Inc. will post ($0.69) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/09/insider-selling-chemocentryx-inc-ccxi-insider-sells-30000-shares-of-stock-updated-updated-updated.html.
A number of analysts have recently commented on CCXI shares. Zacks Investment Research upgraded ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday, July 17th. Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a report on Tuesday.
Several hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new stake in shares of ChemoCentryx during the second quarter valued at approximately $102,000. Trexquant Investment LP boosted its position in ChemoCentryx by 81.1% in the second quarter. Trexquant Investment LP now owns 18,600 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 8,327 shares during the last quarter. State of Wisconsin Investment Board bought a new position in ChemoCentryx during the second quarter valued at $178,000. First Quadrant L P CA bought a new position in ChemoCentryx during the second quarter valued at $219,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in ChemoCentryx during the first quarter valued at $189,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Stock Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related stocks with our FREE daily email newsletter.